2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-117597
    YM440 163300-58-1 98%
    YM440 is an orally active oxadiazolidinedione analog. YM440 ameliorates hyperglycemia without changing PPARy activity, adipocyte differentiation, or fat weight. YM440 is used in the study for non-insulin-dependent diabetes mellitus (NIDDM).
    YM440
  • HY-117761
    MHY908 1393371-39-5 98%
    MHY908 is a potent dual agonist of PPARα and PPARγ. MHY908 also inhibits melanogenesis through inhibition of mushroom tyrosinase activity.
    MHY908
  • HY-117781
    GW-5823 1356689-41-2 98%
    GW-5823 is a selective CCK-AR agonist with an EC50 of 70 nM. GW-5823 can be studied in research on obesity.
    GW-5823
  • HY-117787
    TUG-905 1390641-90-3 98%
    TUG-905 is a potent GPR40 agonist with an pEC50 value of 7.03. TUG-905 increases hypothalamic cell proliferation and survival. TUG-905 reduces body mass and increases the POMC mRNA expression.
    TUG-905
  • HY-117817
    Ranelic acid 135459-90-4 98%
    Ranelic acid is an organic acid with metal cation chelating activity. Ranelic acid can be used to inhibit osteoporosis and increase bone mineral density. Ranelic acid derivatives exhibit highly substituted thiophene ring structures.
    Ranelic acid
  • HY-117828
    PF-04756956 1228934-52-8 98%
    PF-04756956 is a highly potent type 1 cholecystokinin receptor (CCK1R) agonist (EC50=0.47 nM). PF-04756956 is promising for research of obesity and related metabolic disorders.
    PF-04756956
  • HY-117843
    Ppc-1 1245818-17-0 98%
    Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.
    Ppc-1
  • HY-117847
    LLY-2707 1621865-33-5 98%
    LLY-2707 is a selective glucocorticoid receptor (GR) antagonist. LLY-2707 is promising for research of diabetes and psychiatric disorders such as schizophrenia.
    LLY-2707
  • HY-117848
    PDE8B-IN-1 hydrochloride 1305116-67-9 98%
    PDE8B-IN-1 hydrochloride (compound 42) is a potent, selective PDE8B inhibitor with a IC50 value of 1.5 nM. PDE8B-IN-1 hydrochloride can be used in the study of diabetes.
    PDE8B-IN-1 hydrochloride
  • HY-117871
    Naphthol AS-OL 135-62-6 99.05%
    Naphthol AS-OL (C.I. 37530) is a glucuronide taht can be used as a substrate of β-glucuronidase. Naphthol AS-OL can be used to detect β-glucuronidase activity.
    Naphthol AS-OL
  • HY-118092
    JWU-A021 1403610-23-0 98%
    JWU-A021 is a GLP-1 secretagogue with an EC50 of 1.9 μM. JWU-A021 activates the TRPA1 cation channel to promote calcium ion influx and increase intracellular calcium levels in enteroendocrine cells and TRPA1-transfected cells. By activating the TRPA1 channel, JWU-A021 stimulates the secretion of GLP-1 from intestinal enteroendocrine cells and intestinal L cells. JWU-A021 is applicable to research related to type 2 diabetes.
    JWU-A021
  • HY-118386
    H2-005 1060478-12-7 98%
    H2-005 is a compound that selectively inhibits diacylglycerol acyltransferase 2 (DGAT2) and has the activity to inhibit triacylglycerol synthesis in hepatocytes and preadipocytes. H2-005 significantly reduces triacylglycerol biosynthesis in HepG2 hepatocytes and 3T3-L1 preadipocytes. H2-005 exhibits specific inhibitory activity in DGAT2-overexpressing HEK293 cells. H2-005 almost completely inhibits lipid droplet formation in 3T3-L1 cells when co-treated with a DGAT1 inhibitor. H2-005 will contribute to DGAT2-related lipid metabolism research and the development of drugs to inhibit metabolic diseases.
    H2-005
  • HY-118434
    3,4-Methylenedioxychalcone 644-34-8 98%
    3,4-Methylenedioxychalcone (Compound 40) is an α-glucosidase inhibitor with an IC50 of 1870 μM. 3,4-Methylenedioxychalcone is applicable to the research of type 2 diabetes.
    3,4-Methylenedioxychalcone
  • HY-118523
    AL-321 74772-68-2 98%
    AL-321 is an insulin sensitizer. AL-321 exhibits significant hypoglycemic and hypolipidemic activities in insulin resistance models. AL-321 can be used in the research of hereditary obesity-related diabetes.
    AL-321
  • HY-118608
    2α-Methyl androsterone 6961-54-2 98%
    2α-Methyl androsterone is an anabolic androgenic steroid metabolite of mesterolone and drostanolone.
    2α-Methyl androsterone
  • HY-118652
    Δ17-6-keto Prostaglandin F1α 68324-95-8 98%
    Δ17-6-keto Prostaglandin F1α (Δ17-6-keto PGF1α) is a cyclooxygenase (COX) product of eicosapentaenoic acid (EPA) in various tissues such as seminal vesicles, lung, Polymorphonuclear leukocytes, and ocular tissues. Δ17-6-keto PGF1α and other 3-series COX products from EPA, such as PGF3α, PGE3, and thromboxane B3, may be involved in the reduced incidence of glaucoma in patients on a marine-rich (EPA-rich) diet.
    Δ17-6-keto Prostaglandin F1α
  • HY-118709
    Ro 23-7637 107071-66-9 98%
    Ro 23-7637 is an orally active, efficacious antiobesity agent.
    Ro 23-7637
  • HY-118761
    5,6-Epoxyretinoic acid 13100-69-1 98%
    all-trans-5,6-epoxy Retinoic acid (5,6-epoxy RA) is an agonist of all isoforms of the retinoic acid receptor (RAR; EC50s=77, 35, and 4 nM for RARα, RARβ, and RARγ, respectively). 5,6-epoxy RA (1 μM) also induces growth arrest of MCF-7 and NB4 cells in vitro. It is a natural metabolite of all-trans retinoic acid, which is a metabolite of vitamin A.
    5,6-Epoxyretinoic acid
  • HY-118779
    Rhazimine 93772-08-8 98%
    Rhazimine is an indole alkaloid that is a dual inhibitor of arachidonic acid metabolism and platelet activating factor-induced platelet aggregation.
    Rhazimine
  • HY-118786
    Tamoxifen analog II 59130-21-1 98%
    Tamoxifen analog II, a cyclopropyl derivative of Stilbene, is a nonsteroidal antiestrogen. Tamoxifen analog II has antiestrogenic activity. Tamoxifen analog II inhibits the growth of DMBA (HY-W011845)-induced rat mammary tumors.
    Tamoxifen analog II
Cat. No. 상품명 / Synonyms Application Reactivity